Eshallgo Inc. Highlights Strong Momentum Across Global Shares; Highlights on Recent Operational Developments and Strategic U.S. Expansion

Eshallgo Inc. Highlights Strong Momentum Across Global Shares; Highlights on Recent Operational Developments and Strategic U.S. Expansion GlobeNewswire November 17, 2025 New York, Nov. 17, 2025 (GLOBE NEWSWIRE) — Shanghai, November 17, 2025 – Eshallgo Inc. (“Eshallgo” or the “Company”) (Nasdaq: EHGO), a leading provider of integrated office and enterprise technology along with a suite […]

SNPS STOCK LOSS: Synopsys, Inc. Faces Securities Fraud Class Action due to IP Underperformance – Contact BFA Law if You Suffered Losses

(NASDAQ:SNPS), NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Synopsys, Inc. (NASDAQ: SNPS) and certain of the Company's senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal

BYND STOCK LOSS: Beyond Meat, Inc. Faces Securities Fraud Class Action Investigation due to Impairment Charge – Contact BFA Law if You Suffered Losses

(NasdaqGM:BYND), NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Beyond Meat, Inc. (NASDAQ: BYND) for potential violations of the federal securities laws. If you invested in Beyond Meat, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/beyond-meat-inc-class-action-investigation. Why Is Beyond Meat

SNPS STOCK LOSS: Synopsys, Inc. Faces Securities Fraud Class Action due to IP Underperformance – Contact BFA Law if You Suffered Losses

SNPS STOCK LOSS: Synopsys, Inc. Faces Securities Fraud Class Action due to IP Underperformance – Contact BFA Law if You Suffered Losses GlobeNewswire November 17, 2025 NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Synopsys, Inc.

BYND STOCK LOSS: Beyond Meat, Inc. Faces Securities Fraud Class Action Investigation due to Impairment Charge – Contact BFA Law if You Suffered Losses

BYND STOCK LOSS: Beyond Meat, Inc. Faces Securities Fraud Class Action Investigation due to Impairment Charge – Contact BFA Law if You Suffered Losses GlobeNewswire November 17, 2025 NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Beyond Meat, Inc. (NASDAQ: BYND) for

Iron Cap Group Introduces Next-Generation Market Access Engine for Rapid Activation

PARIS, Nov. 17, 2025 (GLOBE NEWSWIRE) — Iron Cap Group today unveiled its next-generation Market Access Engine, a system developed to minimize latency between account creation and market entry. The technology incorporates automated approval routing, intelligent verification layers, and load-optimized infrastructure to handle large user volumes with minimal processing time. “Our technology delivers immediate responsiveness,”

Rigel Announces Publication of Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R/R mIDH1 AML in the Journal of Hematology & Oncology

— Olutasidenib continued to demonstrate durable efficacy and a manageable safety profile in a broad range of patients with R/R mIDH1 AML, including those previously treated with venetoclax-based regimens — Rigel advances its strategic collaborations to further evaluate olutasidenib with the activation of a fifth study with MD Anderson and enrollment of the first patient

PRA Group to Participate in Upcoming Investor Events

PRA Group, Inc. (Nasdaq: PRAA) (the “Company”), a global leader in acquiring and collecting nonperforming loans, announced today that management is scheduled to participate at the following investor events: https://mma.prnewswire.com/media/819349/PRA_Logo.jpg The Citizens Financial Services ConferenceDate: Tuesday, November 18, 2025Format: 1×1 and small group meetings onlyLocation: Lotte New York Palace, New York, New YorkCompany Participants: President

Biotheryx Announces Completion of Enrollment in Phase 1a Clinical Trial of BTX-9341 for the Treatment HR+/HER2- Breast Cancer

Topline data readout from Phase 1a clinical trial expected in Q1 2026 Biotheryx, Inc., a biopharmaceutical company focused on the discovery and development of first-in-class protein degraders for cancer and inflammatory diseases, today announced the completion of enrollment in the ongoing Phase 1a clinical trial of BTX-9341, a potent and selective CDK4/6 degrader, for the

Scroll to Top